Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Hematology. American Society of Hematology. Education Program - 1 Jan 2009

Ottmann Oliver G, Pfeifer Heike

Abstract excerpt

The tyrosine kinase inhibitor (TKI) imatinib has become an integral part of front-line therapy for Ph(+) ALL, with remission rates exceeding 90% irrespective of whether imatinib is given alone or combined with chemotherapy. Treatment outcome with imatinib-based regimens has improved compared with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Cortex Hormones
Share to Antibodies, Bispecific
Share to Dasatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm, Residual

Share to Philadelphia Chromosome

Share to Salvage Therapy

Share to Secondary Prevention

Share to Transplantation Conditioning

Source

Identifiers

PMID: 20008223
DOI: 10.1182/asheducation-2009.1.371

Genes

SCT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20008223-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).PMID 20008223Read ↗

Management of adult Ph-positive acute lymphoblastic leukemia.Semantic proximity Read ↗

Current management of Philadelphia chromosome positive ALL and the role of stem cell transplantationSemantic proximity Read ↗

First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults.Semantic proximity Read ↗

Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challengesSemantic proximity Read ↗

Philadelphia Chromosome–Positive Acute Lymphocytic Leukemia: A New Era of ChallengesSemantic proximity Read ↗

How has the management of Ph+ acute lymphoblastic leukemia (ALL) changed over the years.Semantic proximity Read ↗

Ph+ ALL: new approaches for upfront therapySemantic proximity Read ↗

Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia?Semantic proximity Read ↗

Tyrosine Kinase Inhibitor Use in Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic AnemiaSemantic proximity Read ↗

Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia in Adults: A Broader Range of Options, Improved Outcomes, and More Therapeutic DilemmasSemantic proximity Read ↗

Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.